Evan David Seigerman
Stock Analyst at BMO Capital
(0.93)
# 1895
Out of 5,218 analysts
36
Total ratings
28.57%
Success rate
18.32%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Replimune Group | Maintains: Outperform | 14 18 | 12.53 | 43.66% | 2 | Nov 22, 2024 | |
AbbVie | Maintains: Outperform | 228 208 | 173.5 | 19.88% | 5 | Nov 12, 2024 | |
Regeneron Pharmaceut... | Maintains: Outperform | 1300 1190 | 730.7 | 62.86% | 5 | Nov 1, 2024 | |
Merck & Co | Maintains: Outperform | 150 136 | 102.09 | 33.22% | 2 | Nov 1, 2024 | |
Novo Nordisk | Maintains: Outperform | 160 156 | 106.85 | 46% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 52 57 | n/a | n/a | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 83 100 | 31.19 | 220.62% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 336 355 | 270.45 | 31.26% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 33 36 | 25.59 | 40.68% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 31 72 | n/a | n/a | 4 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 9 3 | 6.8 | -55.88% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 369 396 | 789.07 | -49.81% | 1 | Sep 6, 2022 |